Skip to main content

Day: November 5, 2025

Partners Value Split Corp. Announces US$100,000,000 Public Offering of Class AA Preferred Shares, Series 17

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) — Partners Value Split Corp. (the “Company”) announced today that it has entered into an agreement to sell 4,000,000 Class AA Preferred Shares, Series 17 (the “Series 17 Preferred Shares”) to a syndicate of underwriters led by Scotiabank, BMO Capital Markets, CIBC Capital Markets, RBC Capital Markets and TD Securities Inc. on a bought deal basis. The Series 17 Preferred Shares will be issued at a price of US$25.00 per share, for gross proceeds of US$100,000,000. The Series 17 Preferred Shares will carry a fixed coupon of 5.25% and will have a final maturity of January 31, 2033. The Series 17 Preferred Shares have a provisional rating of Pfd-2 from DBRS Limited. The net proceeds of the offering will be used...

Continue reading

UTime Limited Actively Expands Global Smart Wearable Device Market

UTime LimitedUTime Limited Actively Expands Global Smart Wearable Device MarketUTime LimitedSmart Wearable DevicesSHENZHEN, China, Nov. 05, 2025 (GLOBE NEWSWIRE) — UTime Limited (Nasdaq: WTO) today announced that it is actively promoting its smart wearable devices to more international markets through its existing global distribution channels and partner network.Leveraging its experience in supply chain management and product development accumulated in the mobile device sector, the company is committed to introducing its newly launched health-focused smart wearable products, including smartwatches and smart rings, to multiple overseas markets where it has established business connections. The company believes that its products’ balance of functional design and cost-effectiveness will help them gain competitiveness...

Continue reading

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, today announced that its abstract, “Adaptive Phase 2/3 Study for PCS499 (499) in Patients with Focal Segmental Glomerulosclerosis (FSGS)”, has been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2025, taking place November 5–9, 2025, in Houston, Texas. The poster will be presented as part of the session “Glomerular Clinical Trials: From Data to Impact” on Friday, November 7, 2025, from 10:00 a.m. to 12:00 p.m. Central Time. The poster board number is FR-PO0829. PCS499 is an analog of a metabolite of pentoxifylline (PTX). PTX has been shown to decrease proteinuria...

Continue reading

MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that the Company will release its third quarter 2025 financial results before the market opens on Friday, November 14th. The announcement follows MiNK’s late-breaking presentation at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where new clinical data from the company’s agenT-797 iNKT cell therapy demonstrated durable immune reconstitution and signals of activity in patients with advanced solid tumors. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss financial results, recent clinical progress including SITC data,...

Continue reading

HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes

New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the publication of a new preprint from the HiFi Solves EMEA Consortium, “HiFi sequencing accurately identifies clinically relevant variants in paralogous genes.” The study shows that PacBio HiFi sequencing combined with Paraphase, a dedicated haplotype-based variant caller, uncovered all known clinically relevant variants present in the study population – even in the hardest-to-sequence regions of the genome – demonstrating its readiness...

Continue reading

Scatec ASA: Successful placement of senior unsecured green bonds

Oslo, 5 November 2025: Scatec ASA (“Scatec”) has successfully issued a NOK 1,000 million 4.25-year senior unsecured green bond issue with a coupon of 3 months NIBOR + 2.85% p.a. The net proceeds of the green bond issue shall be applied towards repayment of outstanding corporate interest-bearing debt and general corporate purposes as set out in the Green Financing Framework. The bond will extend Scatec’s corporate maturity profile and enhance its financial flexibility. Scatec remains committed to continue deleveraging on corporate level, targeting NOK 4 billion in gross corporate interest-bearing debt by 2030. Arctic Securities, DNB Carnegie, Nordea and SB1 Markets acted as Joint Lead Managers in connection with the placement of the new bond issue. An application will be made for the bonds to be listed on Oslo Børs. For further...

Continue reading

Veeco Receives Propel®300 MOCVD System Order From Leading GaN-on-Si Power Semiconductor IDM

Supports Rapidly Growing GaN Device Market Driven by Demand for Power Efficiency for Data Center, Industrial, and Automotive Applications PLAINVIEW, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) — Veeco Instruments Inc. (NASDAQ: VECO) announced today receipt of an order for a Propel®300 system from a major power semiconductor integrated device manufacturer (IDM) for gallium nitride (GaN) epitaxy on 300mm silicon (Si) wafers. This order cements Veeco’s position as a leader in 300mm MOCVD technology, building on years of experience including previous shipments of the Propel®300 platform for various applications across the compound semiconductor industry. “Qualifying Propel®300 for 300mm GaN-on-Si epitaxy for power devices is a significant achievement in the path to widespread adoption of GaN technology,” commented Anil Vijayendran, Vice President,...

Continue reading

STMicroelectronics: Jean-Marc Chery, STMicroelectronics’ President and CEO to speak at Morgan Stanley investor conference

Jean-Marc Chery, STMicroelectronics’ President and CEO to speak at Morgan Stanley investor conference Geneva, November 5, 2025 – STMicroelectronics N.V. (“ST”) (NYSE: STM) President and Chief Executive Officer Jean-Marc Chery will speak at the Morgan Stanley 25th European Technology, Media & Telecom Conference in Barcelona on Wednesday, November 12, 2025 at 11:00 am CET. A live webcast (listen-only mode) of the conference will be accessible at ST’s website, https://investors.st.com, and will be available for replay until November 26, 2025. About STMicroelectronicsAt ST, we are 50,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to...

Continue reading

Notice convening Extraordinary General Meeting

        Company Announcement No 56/2025Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk5 November 2025  Dear Sirs Notice convening Extraordinary General Meeting Sydbank’s Extraordinary General Meeting will be held on Thursday 4 December 2025 at 2:00pm. The notice and the agenda for the general meeting including appendices have been attached to this announcement. Yours sincerely Sydbank A/SAttachmentsSM 56 UKNotice Convening the Extraordinary General Meeting of Sydbank

Continue reading

Gevo North Dakota Sells Its Remaining 2025 45Z Production Tax Credits for $30 Million, Bringing the Contracted Total for the Year to $52 Million

Gevo continues to unlock the value of efficient ethanol production and carbon sequestration through the sale of Section 45Z tax credits. ENGLEWOOD, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) announced the contracted sales of its remaining Section 45Z Clean Fuel Production Credits for 2025 from its Gevo North Dakota facility (“GevoND”), totaling $30 million, to Stifel Financial Corp. and Capital Community Bank, bringing the total sales for 2025 to $52 million, when combined with the previously announced $22 million worth of credits sold in July. These production tax credits were generated based on volumes of ethanol produced at GevoND and taking into account operating carbon sequestration and operating efficiencies. Gevo believes it is one of the first ethanol producer to sell Section 45Z credits directly...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.